Cart
sales@molnova.com
XD14
CAS No. 1370888-71-3
XD14( —— )
Catalog No. M22392 CAS No. 1370888-71-3
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 110 | In Stock |
|
| 5MG | 93 | In Stock |
|
| 10MG | 163 | In Stock |
|
| 25MG | 330 | In Stock |
|
| 50MG | 516 | In Stock |
|
| 100MG | 728 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameXD14
-
NoteResearch use only, not for human use.
-
Brief DescriptionXD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
-
DescriptionXD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorBET bromodomain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1370888-71-3
-
Formula Weight421.51
-
Molecular FormulaC20H27N3O5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (296.55 mM)
-
SMILESCCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Daqiang P , Michel K , Lucas W , et al. Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7[J]. International Journal of Molecular ences, 2016, 17(10).
molnova catalog
related products
-
PBRM1-BD2-IN-2
PBRM1-BD2-IN-2, a selective and cell-active inhibitor of the polybromo-1 (PBRM1) bromodomain, exhibits binding affinity and inhibitory activity specifically targeting the PBRM1-BD2 domain, with Kd and IC50 values of 9.3 μM and 1.0 μM, respectively.
-
BY27
BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.
-
WAY-309060
WAY-309060 is a BRD4 small molecule inhibitor with antitumor activity.
